story of the week
Ibrutinib Effective for Patients with Relapsed or Refractory Chronic Lymphocytic Leukaemia With 17p Deletion
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ibrutinib for Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia With 17p Deletion (RESONATE-17): A Phase 2, Open-Label, Multicentre Study
Lancet Oncol 2016 Sep 13;[EPub Ahead of Print], S O'Brien, JA Jones, SE Coutre, AR Mato, P Hillmen, C Tam, A Österborg, T Siddiqi, MJ Thirman, RR Furman, O Ilhan, MJ Keating, TG Call, JR Brown, M Stevens-Brogan, Y Li, F Clow, DF James, AD Chu, M Hallek, S StilgenbauerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.